A new comprehensive treatment for peritoneal metastases using cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion
Hyperthermic Oncology from Bench to Bedside, Page: 371-396
2016
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures1
- Readers1
Book Chapter Description
A game-changing therapy for peritoneal metastasis (PM), now called ‘comprehensive treatment’ was first established in the late 1990s. The treatment consists of aggressive cytoreductive surgery (CRS) combined with perioperative intraperitoneal/systemic chemotherapy. PM is considered as local disease, and the rationale behind the treatment is to remove macroscopic tumors and eradicate residual micrometastasis using perioperative chemotherapy (POC). Comprehensive treatment consists of laparoscopic evaluation of the tumor load, POC, and CRS. POC includes six procedures including laparoscopic hyperthermic intraperitoneal chemotherapy (LHIPEC), neoadjuvant intraperitoneal/systemic chemotherapy (NIPS), hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC).
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85006736307&origin=inward; http://dx.doi.org/10.1007/978-981-10-0719-4_34; http://link.springer.com/10.1007/978-981-10-0719-4_34; http://link.springer.com/content/pdf/10.1007/978-981-10-0719-4_34; https://dx.doi.org/10.1007/978-981-10-0719-4_34; https://link.springer.com/chapter/10.1007/978-981-10-0719-4_34
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know